CellWell record HH-4964
Targeting mitochondrial metabolism in renal cell carcinoma with melatonin: Preclinical evidence and clinical perspectives.
Noroozi-Karimabad M; Alimohammadi M; Mafi A; Hedayati N; Razavi FT; Cho WC; Mohammad-Sadeghipour M; Farahani N; Entezari M; Daneshi S; Hushmandi K; Taheriazam A
Tissue & cell ยท 2026
In plain language
An expert review on Melatonin found that further clinical trials should concentrate on dose optimization, biomarker-guided patient selection, and combination regimens that include immune checkpoint blockade.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-4964
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.